Cibc World Markets Corp Boosts Holdings in Solventum Co. (NYSE:SOLV)

Cibc World Markets Corp boosted its holdings in Solventum Co. (NYSE:SOLV) by 15.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,179 shares of the company’s stock after purchasing an additional 2,960 shares during the quarter. Cibc World Markets Corp’s holdings in Solventum were worth $1,465,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its position in shares of Solventum by 137.3% during the third quarter. Victory Capital Management Inc. now owns 53,589 shares of the company’s stock worth $3,736,000 after acquiring an additional 31,007 shares during the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Solventum during the 3rd quarter valued at about $315,000. Natixis Advisors LLC increased its holdings in shares of Solventum by 271.4% in the third quarter. Natixis Advisors LLC now owns 47,616 shares of the company’s stock worth $3,320,000 after purchasing an additional 34,797 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of Solventum in the third quarter worth about $231,000. Finally, Prospera Private Wealth LLC bought a new position in Solventum during the third quarter valued at approximately $35,000.

Solventum Stock Down 1.3 %

Shares of NYSE:SOLV opened at $74.00 on Friday. The firm has a market capitalization of $12.80 billion and a PE ratio of 26.91. The business has a 50 day simple moving average of $75.17 and a two-hundred day simple moving average of $71.51. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Analysts Set New Price Targets

Several analysts have recently issued reports on SOLV shares. Piper Sandler upped their price objective on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a report on Friday, February 28th. The Goldman Sachs Group upped their price target on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Morgan Stanley lifted their price objective on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th. Wells Fargo & Company upped their target price on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Finally, Mizuho lifted their price target on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.